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Summary hnRNP A2/B1 has been suggested as a useful early detection marker for
lung carcinoma. hnRNP A2/B1 is a member of a large family of heterogeneous nuclear
ribonucleoproteins (hnRNP proteins) involved in a variety of functions, including
regulation of transcription, mRNA metabolism, and translation. In lung cancer, we
have evaluated the expression and cellular localization of several members of the
hnRNP family, hnRNP A1, A2, B1, C1, C2 and K. 16 cell lines (SCLC and NSCLC) and
biopsies from 32 lung cancer patients were analyzed. Our results suggest that, besides
hnRNP A2/B1, the expression of other members of the hnRNP family is altered both in
SCLC and NSCLC. In the biopsies, negative or low expression of the hnRNP proteins
analyzed was observed in normal epithelial cells whereas lung cancer cells showed
highly intense nuclear or cytoplasmic immunolocalization. In all the lung cancer cell
lines, the mRNA for all the hnRNP proteins was detected. In general, higher levels of
hnRNP mRNAs were found in SCLC as compared with NSCLC. Our results also suggest
that the expression and processing of each hnRNP protein in lung cancer is
independently regulated and is not exclusively related to proliferation status. In
SCLC cell lines, hnRNPA1 protein expression correlated with that of Bcl-xL. In the lung
cancer cell lines, hnRNP K protein localization varied with the cellular confluence.
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1. Introduction
The expression of a gene encoding a functional
protein is initiated with the production of an
immature pre-mRNA molecule. Virtually all mRNA
molecules in eukaryotes are processed to some
degree after they are synthesized. During their
processing, the pre-mRNAs are subjected to mod-
ification in an operation controlled in a tissue- and
developmental-specific manner. The normal func-
tioning of this process is frequently altered in
human diseases. It has been reported that 15% of
human genetic diseases are caused by mutations
that affect mRNA splicing [1]. In cancer, the
expression of alternatively spliced mRNAs encoding
altered forms of proteins has been related to
tumorigenesis and tumor progression. BRCA1, Cy-
clin D1, mdm2, FHIT, TSG101, VEGF and CD44 are
good examples of a rapidly growing list of cancer-
related genes with aberrant splicing forms [2/7].
The mRNA processing, as well as other mRNA-
related cell activities, are regulated by specific
RNA-binding proteins such as the members of the
hnRNP family [8]. About 20 major hnRNP proteins,
from A1 to U, have been described and included in
the family by their capacity to bind to pre-mRNA
with no unique structural motif or function. Among
the family, hnRNP A, D, E, I, and K have been
reported to shuttle between the nucleus and the
cytoplasm and some of them interact with each
other forming hnRNP complexes [9]. The best
characterized complex in mammalian cells is the
40S-ribonucleoprotein core particle associated to
the pre-mRNA. hnRNP A, B and C represent the
major proteins present in the core particle. They
exist in a fixed molecular ratio forming apparently
three different heterotetramers, (A1)3B2, (C1)3C2
and (A2)3B1, although only two of them, (C1)3C2
and (A2)3B1, have been isolated and characterized
[10,11]. Apart from this fixed stoichiometry, there
is not a fixed set of hnRNP proteins that bind to
every pre-mRNA. Rather, specific combinations of
hnRNP proteins are thought to cluster on each type
of pre-mRNA. This particular combination would
depend on the mRNA sequence and the repertoire
of hnRNP proteins present in the nucleus at the
moment of transcription [8]. hnRNP proteins are
involved in a variety of key cellular functions such
as mRNA splicing [12], stabilization [13,14], nu-
cleo-cytoplasmic transport [15/17], and transcrip-
tional control [18]. Some of them can also control
the transcription of specific genes [19,20]. Several
evidences, summarized in the following paragraph,
support the hypothesis that the hnRNP proteins
may be relevant in human carcinogenesis.
Overexpression of hnRNP proteins has been
reported in several types of cancers. hnRNP A1 is
overexpressed in oligodendrogliomas [21] and
chronic myelogenous leukemia [22]. hnRNP A1
expression is also increased in myeloid progenitor
cells expressing the BRC/ABL oncoprotein. In these
cells, an alteration of hnRNP A1 normal functioning
results in a decrease of colony formation and
tumorigenesis of these transformed cells, in part
due to a downregulation of the antiapoptotic
factor Bcl-xL [22]. hnRNP A2 and hnRNP B1 are
overexpressed in lung, breast, pancreatic and
esophageal cancer [23/27]. In a retrospective
study with sputum from high risk individuals, the
use of a monoclonal antibody specific for hnRNP
A2/B1 showed 88% specificity in the prediction of
lung cancer 2 years in advance of any clinical
evidence. Subsequent prospective studies have
accurately predicted that 65% of individuals with
a high immunoreactivity for this antibody in spu-
tum would develop lung cancer in the first year of
follow-up [26]. Using a polyclonal antibody specific
for hnRNP B1, it has been suggested that hnRNP B1,
and not hnRNP A2, is the protein overexpressed in
early stages of lung carcinogenesis, although no
biological explanation has been proposed for this
selective overexpression [28,29]. The upregulation
of hnRNP A2/B1 message in NSCLC has been
associated with microsatellite instability, suggest-
ing that lung tumor cells undergoing progression
frequently overexpress hnRNP A2/B1 [30]. In addi-
tion, hnRNP subcellular localization seems to be an
important factor associated with tumor progres-
sion, as cytoplasmic hnRNP A2/B1 immunoreactive
cells have a higher frequency of microsatellite
instability and loss of heterozygosity than do cells
with nuclear immunoreactivity [31]. A study of the
hnRNP A2/B1 expression during mammalian lung
development revealed a regulated expression pat-
tern of hnRNP A2/B1 during fetal development and
downregulation in normal adult tissues [32]. This
pattern of expression during development and the
reexpression of the protein during tumor progres-
sion is consistent with hnRNP A2/B1 role as an
oncofetal molecule. Although the biological reason
for hnRNP A2/B1 overexpression in cancer is still
not clear, it has been reported to be part of the
molecular machinery that regulates telomere for-
mation and/or stabilization [33], and has been also
associated to the control of apoptosis [33,34].
These two functions may also be regulated by the
other members of the 40S-ribonucleoprotein core
particle, hnRNP A1 and hnRNP C1/C2 [33/35].
Other hnRNP protein potentially relevant in
tumorigenesis is hnRNP K. In the nucleus, this
protein can bind directly to the promoter region
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of the human c-myc gene and functions as a
transcription factor [19]. When localized to the
cytoplasm, hnRNP K inhibits translation of specific
mRNAs such as 15-lipoxygenase mRNA [36]. In
breast cancer cells, hnRNP K significantly enhances
cell proliferation and anchorage-independent
growth through a growth factor dependent me-
chanism [37].
Several authors have reported an association of
hnRNP expression with actively proliferating cells
[38/40]. It is still not clear whether the over-
expression of the hnRNP proteins in cancer is a
tumor specific event or rather it is a mere
consequence of the accelerated mRNA metabolism
common to highly proliferative cancer cells. To
clarify the relevance of the members of the hnRNP
protein family in cancer, a systematic evaluation of
the status of these proteins in normal versus tumor
cells was required. It is also interesting to carry out
detailed studies on the balance in the expression of
splicing variants of individual hnRNP proteins, such
as hnRNP A2/B1 and hnRNP C1/C2, in relation to
carcinogenesis. Due to the diverse functions asso-
ciated to each hnRNP protein (both in the nucleus
and cytoplasm), other important aspect that may
give light into the hnRNP functions implicated in
lung cancer is the determination of the cellular
localization of each particular hnRNP protein. To
achieve these purposes, we decided to character-
ize in lung cancer the coordinated expression and
distribution of several hnRNP proteins, rather than
the isolated expression of a single one. We studied
the expression of hnRNP A1, A2, B1, C1, C2 and K in
normal lung epithelium, 16 lung cancer cell lines
and 32 biopsies from lung cancer patients. Based on
our results, we conclude that these hnRNP proteins
are abnormally expressed in lung cancer as com-
pared with normal respiratory epithelium. In the
present paper we also discuss about the physio-
pathological consequences of this alteration.
2. Materials and methods
2.1. Cell lines
A range of lung cancer cell lines including eight
NSCLC and eight SCLC cell lines (American Type
Culture Collection, ATCC, Manassas, VA) were
selected for the analysis. Cells were grown in the
medium specified by ATCC (DMEM or RPMI 1640;
Life Technologies, Inc., Carlsbad, CA) and supple-
mented with 10% fetal bovine serum and penicillin-
streptomycin. Primary cultures of human bronchial
epithelium cells (NHBE) grown in supplemented
bronchial epithelial cell growth media (BGEM†,
Clonetics, San Diego, CA) were also used. For all
the cell lines, logarithmic phase growing cells were
harvested at 70/80% confluence. For immunocy-
tochemical techniques cells were processed differ-
ently depending on the optimal protocol
implemented for each antibody. For hnRNP A1 and
hnRNP C1/C2 cells were trypsinized (when adher-
ent), pelleted, embedded in agarose, fixed in
Bouin’s fluid, embedded in paraffin and sectioned.
Alternatively, for hnRNP A2/B1 and hnRNP K,
adherent cells were grown directly on the surface
of the microscope slides and then fixed in Sacco-
manno’s fixative followed by acetone/methanol
(1:1); non-adherent cells were pelleted, fixed as
before and placed on microscope slides with the
Cytospin† 3 cell Preparation System (Shandon,
Pittsburg, PA).
2.2. Lung cancer biopsies
Lung carcinoma samples from stage I and II
patients were obtained under an institution-ap-
proved human tissue procurement protocol. Tu-
mors, adjacent areas to the tumor and distant
(usually more than 5 cm) normal uninvolved tissue
were obtained and analyzed. Samples were con-
sistently immersed in buffered formalin within 20
min from surgical resection. All the samples were
removed from the fixative solution after 24 h
fixation. Tissues were then paraffin embedded
and sectioned. A total of 30 NSCLC cases were
studied, including 15 squamous cell carcinomas,
ten adenocarcinomas, four bronchioloalveolar tu-
mors, and one carcinoid. Samples from two pa-
tients that were diagnosed with SCLC after
pathological analysis of the surgical pieces were
also included in this series. Patients ranged from 42
to 87 years of age, all of them were current or
former smokers except for one. Sex distribution
was five females and 27 males.
2.3. Antibodies
The mouse monoclonal antibody (MoAb) 703D4
(IgG2bK) specific for hnRNP A2/B1 was a kind gift
from Dr J.L. Mulshine (National Cancer Institute,
Bethesda, MD). The antibodies against hnRNP A1
(4B10; IgG2a) and hnRNP C1/C2 (4F4; IgG1) both
MoAb were a kind gift from Professor G. Dreyfuss
(Howard Hughes Medical Institute, Philadelphia,
PA). The affinity purified-polyclonal antibody
against hnRNP K was developed by Dr F. Lecanda
(University of Navarra, Pamplona, Spain). The
antibodies against two splicing forms of one single
gene (A2/B1 and C1/C2) were directed against the
common sequences of both proteins. The rabbit
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polyclonal antibody against Bcl-xS/L was purchased
from Santa Cruz Biotechnology (Santa Cruz, CA).
The specificity of each antibody was confirmed by
Western blot analysis. For immunocytochemistry
the working dilutions for the hnRNP antibodies
were: 703D4, 1/100; 4B10, 1/6000; 4F4, 1/6000;
and for the antibody against hnRNP K, 1/50 for the
cell lines and 1/100 for the lung biopsies. For
Western blot analysis, the dilutions of the anti-
bodies were: Bcl-xS/L, 1/1000; 4B10, 1/2000, and
hnRNP K, 1/1000.
2.4. Immunocytochemistry
Sections (3 mm) were deparaffinized and incu-
bated overnight at 4 8C with the corresponding
antibody. Only the biopsies incubated with the
antibody against hnRNP K needed previous treat-
ment with citrate buffer and microwave oven. The
next steps of the protocol were optimized for each
one of the antibodies used as follows. For the 4B10
antibody, the ENVISION† (DAKO, Carpinteria, CA)
system was applied for 30 min; for 703D4, we used
universal secondary antibody containing rabbit
anti-mouse IgG (DAKO) for 30 min followed by
incubation with ABC complexes (DAKO) for 30 min
for the cell lines, and the ENVISION† (DAKO)
system (30 min) was applied for the lung biopsies.
In the case of 4F4 antibody, universal secondary
antibody containing rabbit anti-mouse IgG (DAKO)
(30 min) and ABC complex (30 min) were used.
Finally, for the antibody against hnRNP K, we also
used ENVISION† (DAKO) (30 min). The immunos-
taining was then developed with diaminobenzidine
and counterstained with hematoxylin. Negative
controls by omission of primary antibodies were
done for all the cases.
2.5. Western blot analysis
Total protein extracts from cell lines were
electrophoretically fractionated on 4/12% Bis-Tris
gels (Novex, San Diego, CA), transferred to a 0.2
mm nitrocellulose membrane, and blocked with 5%
milk in PBS. Afterwards the membrane was incu-
bated with the primary and secondary antibodies
and developed using the Lumi-LightPLUS Western
Blotting Kit (Roche, Indianapolis, IN) according to
the manufacturer’s instructions.
2.6. Real-time quantitative reverse
transcription-PCR
Expression of the hnRNP A1, A2, B1, C1, C2 and K
genes were characterized by real-time quantitative
reverse transcription-PCR with the ABI PRISMTM
7700 Sequence Detector and the software Se-
quence Detector version 1.6.3. (Perkin/Elmer/
Applied Biosystems, Foster City, CA). RNA was
isolated from all the cell lines with the GIT/Cesium
Chloride method. The reactions were performed
with 2 mg total RNA with minor differences from ABI
7700 manufacturer’s instructions. Relative levels of
the hnRNP mRNA proteins studied expression were
determined by the Ct method. Every assay was
performed in triplicate and two different samples
obtained in separate experiments were analyzed
for each cell line. Primers for hnRNP mRNA
amplification were: hnRNP A1 forward 5?-TCGTCA-
GCTTGCTCCTTTCTG-3?, reverse 5?-ATGACGGCAGG-
GTGAAGAGA-3?; hnRNPA2 forward 5?-TCTCTCTCAT-
CTCGCTCGGC-3?, reverse 5?-CTTACGGAACTGTTCC-
TTTTCTCTCT-3?; hnRNP B1 forward 5?-TCTCTCTCA-
TCTCGCTCGGC-3?, reverse 5?-CGGAACTGTTCCTTT-
TCTCTCTTT-3?; hnRNP C1 forward 5?-AAAAGCAGGT-
GTGAAACGATCTG-3?, reverse 5?-GGAGGTACACGT-
GCTGGGTAA-3?; hnRNP C2 forward 5?-GCGGAGATG-
TACGGGTCAGTA-3?, reverse 5?-GGAGGTACACGTGC-
TGGGTAA-3?; hnRNP K forward 5?-CAGCATTGCAGA-
CGCCATTAT-3?, reverse 5?-GTGGGACACAGGCAAGA-
CGT-3?. The TaqMan probes for the amplified
sequences detection were: hnRNP A1 5?-(6-
Fam)CCGCCGAAGAAGCATCGTTAAAGT-(Tam-
ra)(phosphate)-3 ?, hnRNP A2/B1 5 ?-(6-Fa-
m)AAATCGGGCTGAAGCGACTGAGTCC(Tamra)(pho-
sphate)-3?, hnRNP C1 5?-(6-Fam)CGGAGATGTACGG-
CTCCTCTTTTGA-(Tamra)(phosphate)-3?, hnRNP C2
5?-(6-Fam)CAGAACACCCTTCTCCGTCCCCT-(Tam-
ra)(phosphate)-3? and hnRNP K 5?-(6-Fam)-
CTGTTTCTCTGCTGCACCGACCTC-(Tamra)(pho-
sphate)-3?. All experiments included a GAPDH
internal standard. The primers used for GAPDH
amplification were 5?-GAAGGTGAAGGTCGGAGTC-
3? and 5?-GAAGATGGTGATGGGATTTC-3?. The probe
for GAPDH detection was 5?-(Joe)CAAGCTTCCCGT-
TCTCAGCC-(Tamra)(phosphate)-3?. Quantitative
mRNA levels for each hnRNP gene were expressed
as relative (percentage) comparison to a house-
keeping gene (GAPDH) mRNA.
2.7. Statistical analysis
The values obtained from real-time RT-PCR were
analyzed by U Mann/Whitney test to compare data
between SCLC and NSCLC cell lines. Correlations in
data obtained from the biopsies were analyzed by
Kendall’s correlation test. A P value less than 0.05
was considered to be significant.
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3. Results
In this study we have analyzed the expression of
different hnRNP proteins in a variety of lung cancer
cell lines both SCLC and NSCLC as well as in normal,
hyperplastic and malignant lung tissues. We quan-
tified the gene expression of each hnRNP protein in
eight SCLC and eight NSCLC cell lines by real-time
PCR. The expression levels of each hnRNP protein
were assessed for the same cell lines by immuno-
cytochemistry. For each cell line, we have obtained
a comparative value denoted ahnRNP, consisting in
the addition of the mRNA value from each hnRNP
protein analyzed. Cell line to cell line, ahnRNP
varied ranging from 35.6 (H774) to 129.9 (H510) in
SCLC and from 19.3 (A549) to 33.8 (H676) in the
case of NSCLC. Overall, the average expression of
the hnRNP mRNAs in SCLC was significantly higher
(PB/0.001) than that in NSCLC (average levels
were 75.09/37.1 and 26.29/4.9, respectively).
Finally, we characterized by immunocytochemistry
the expression of these proteins in a series of
biopsies from patients diagnosed for lung cancer,
mainly non-small cell lung cancer at early stages
(stages I or II). Fig. 1 and Table 1 summarize the
expression of hnRNP proteins in the biopsy sam-
ples.
3.1. hnRNP A1
hnRNP A1 was detected in all of the cell lines
(SCLC and NSCLC) analyzed. Average mRNA expres-
sion in SCLC cell lines was 4.3 fold higher than that
in NSCLC cell lines (average mRNA percentage level
13.79/6.4 and 3.29/1.5 respectively, P/0.006),
although not all SCLC cell lines (i.e. N417 and H774)
presented higher levels of expression than the
NSCLC cell lines. H69, H82 and H510 showed the
highest levels of hnRNP A1 message (Fig. 2). In
every cell line, the immunocytochemical analysis
of sectioned cultured cells revealed a strong hnRNP
A1-like staining localized in the nucleus. As a
representative example, Fig. 1e shows hnRNP A1
staining of H1264 cell line. Western blot analysis in
protein extracts from SCLC cells lines also revealed
a high expression of hnRNP A1 (Fig. 3). Interest-
ingly, in most cell lines studied a parallel expres-
sion of hnRNP A1 and Bcl-xL was observed (Fig. 3),
with the clear exception of H446. No Bcl-xS
expression was detected in any of the SCLC cell
lines analyzed. In biopsies, hnRNP A1 was consis-
tently detected both in normal and tumor areas
(Table 1 and Fig. 1a/d). No immunoreactivity for
hnRNP A1 was detected in the alveolar epithelial
cells (Fig. 1a), except in the areas of thickened
(fibrotic) septa where we observed a moderate
epithelial nuclear staining. Normal bronchiolar
epithelium showed hnRNP A1 moderate nuclear
localization in a large proportion of the cells (Fig.
1b). Interestingly, an increase in hnRNP A1 expres-
sion was consistently observed in every area of
hyperplastic type II pneumocytes, which showed
strong nuclear staining for the protein (Fig. 1c). In
bronchiolar hyperplasias, the intensity of hnRNP A1
nuclear staining was higher than that found in
normal bronchiolar cells. All NSCLC biopsies
showed a very marked nuclear staining in almost
100% of the tumor cells (Fig. 1d). In general, the
normal tissue adjacent to the tumor expressed
higher levels of hnRNP A1 than the distal unaf-
fected normal tissue. In the case of the two SCLC
samples, an intense nuclear staining was observed
in all the tumor cells.
3.2. hnRNP A2/B1
Our primer design for real-time RT-PCR allowed
us to distinguish between the two transcripts (A2/
B1) arising from the same gene. All the lung cancer
cell lines analyzed expressed both hnRNP A2 and
hnRNP B1 mRNA. Expression for both transcripts in
SCLC cell lines was almost invariably higher than in
NSCLC cell lines (hnRNP A2: P/0.001; hnRNP B1:
P/0.009), except for hnRNP B1 in H1385 that was
similar to NSCLC levels. Overall, the average
expression of hnRNP A2 mRNA was 7.2 times higher
than that of hnRNP B1 in the case of SCLC (average
mRNA percentage level 25.39/7.9 and 3.59/1.7,
respectively) and 6.3 fold in the case of NSCLC
(average mRNA percentage level 7.59/2.4 and
1.29/0.8, respectively) (Fig. 4). Cell line to cell
line hnRNP A2 to hnRNP B1 ratio varied ranging
from 12.1 (N417) to 3.8 (H69) in SCLC and from
11.8 (H1264) to 3.1 (H1385) in NSCLC, without
significant statistical differences between SCLC
and NSCLC. In all the cell lines studied hnRNP A2/
B1-like immunoreactivity was primary located to
the cytoplasm (Fig. 1j). By immunocytochemistry,
normal lung alveoli and bronchioli were negative
for hnRNP A2/B1 protein (Table 1, Fig. 1f and g).
Half of the cases showed positive cytoplasmic
staining in the hyperplastic epithelial tissue. While
in the alveolar hyperplastic type II pneumocytes a
strong staining was localized in a granular pattern,
the staining of hyperplastic bronchioli was moder-
ate, less common and also granular. About 60% of
the NSCLC biopsies showed a moderate patched
cytoplasmic staining of moderate intensity in
tumors (Fig. 1i). hnRNP A2/B1 expression was
more frequent in adenocarcinomas than in squa-
mous cell carcinomas (79 and 44%, respectively,
P/0.036). Besides, our data indicates that hnRNP
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Fig. 1 Expression of hnRNP proteins is increased in human lung cancer when compared with normal tissues as studied
by immunocytochemistry. The figures include representative examples of the expression of the five hnRNP proteins in
tissues and cell lines. (a/e) hnRNP A1 protein expression. (f/j) hnRNP A2/B1 protein expression. (k/n) hnRNP C1/C2
protein expression. (o/r) hnRNP K protein expression. (a, f, k, and o) Normal alveolar cells. (b, g, l, and p) Normal
bronchiolar cells. (c and h) Type II pneumocyte hyperplasia. (d, i, m, and q) NSCLC tumor cells. (e, j, n, and r) H1264
NSCLC cell line. Original magnification of all the pictures: /500, scale bar/50 mm.
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A2/B1 is preferentially expressed by well or mod-
erately differentiated tumors, concluding that
there exists a correlation (P/0.011) between
histological grade and protein expression: 100% of
well differentiated tumors (n/4) expressed
hnRNP A2/B1, 67% of moderately differentiated
tumors (n/15) expressed the protein and only 37%
of the poorly differentiated tumors (n/8) pre-
sented hnRNP A2/B1 expression. One of the two
SCLC cases included in the study was negative for
hnRNP A2/B1 while the other showed moderate
nuclear and cytoplasmic staining.
3.3. hnRNP C1/C2
hnRNP C1 and hnRNP C2 were expressed by all
the lung cancer cell lines analyzed. Our design for
real-time PCR allowed us to distinguish between
the two transcripts, hnRNP C1 and C2. The mRNA
analysis showed a consistently and remarkably
higher expression of hnRNP C1 when compared
with hnRNP C2 in every cell line from both SCLC
and NSCLC (Fig. 5). In SCLC the hnRNP C1/C2 mRNA
ratio ranged from 170.9 (H69) to 7.9 (H82), in
NSCLC C1/C2 ratio differed from 162.1 (H676) to
4.0 (HTB55 and H1264). Levels for hnRNP C1 and C2
mRNA were the highest in H510. hnRNP C1 mRNA
expression was higher (P/0.004) in SCLC cell lines
(average mRNA level 9.79/5.5) than in NSCLC cell
lines (average level 3.39/1.4). Such differential
expression was not found for hnRNP C2 mRNA
(average mRNA level 0.59/0.4 and 0.49/0.3, re-
spectively, for SCLC and NSCLC cell lines). In all the
cell lines studied a strong nuclear hnRNP C1/C2-
like immunostaining was observed (Fig. 1n). In the
biopsies studied, both normal and tumor lung
epithelial cells were immunoreactive for hnRNP
C1/C2 (Table 1 and Fig. 1k/m). Normal alveolar
and bronchiolar tissue showed moderately intense
nuclear reactivity in 70% of the cases. The epithe-
lial hyperplastic lesions were more intensely
stained than normal tissue and less than the
tumors. 100% of the non-small lung tumors studied
displayed a very strong nuclear staining that
extended to the total area of the tumor. This
Table 1 Expression and localization of hnRNP proteins in 30 normal human lung and NSCLC biopsies by
immunocytochemistry
hnRNP A1 hnRNP A2/B1 hnRNP C1/C2 hnRNP K
Normal alveoli /a / Nb // (50%)c /
Normal bronchioli N /// (75%) / N /// (50%) /
Type II pneumocyte hyper-
plasia
N /// (75%) C ///
(75%)
N /// (75%) N / (25%)
Bronchiolar hyperplasia N//// (75%) C // (50%) N /// (75%) N // (50%)
Tumor N ////
(100%)
C // (75%) N ////
(100%)
N /// (75%)d, C ///
(50%)
a Intensity of staining: / negative; / low; // moderate; /// high; //// very high.
b N, nuclear staining; C, cytoplasmic staining.
c In parenthesis, percentage of stained cells in the positive tissues.
d Two entries for hnRNP K in tumors are included due to the double localization of the protein, both in the nucleus
and the cytoplasm.
Fig. 2 Expression of hnRNP A1 mRNA in lung cancer cell
lines by real time RT-PCR. The y -axis represents the
relation between hnRNP A1 and GAPDH mRNAs in
percentage.
Fig. 3 Comparison of hnRNP A1 and Bcl-xL expression in
various SCLC cell lines. b-Actin expression was used to
assess equal loading.
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intense nuclear staining was also observed in the
two SCLC biopsies.
3.4. hnRNP K
hnRNP K was expressed in every cell line ana-
lyzed. mRNA expression in SCLC cell lines (average
level 22.39/14.9) seemed to be higher than that in
NSCLC cell lines (10.59/2.6) (Fig. 6), although the
difference did not reach statistical significance.
H69, N417 and H510 were the highest hnRNP K
expressing cells among the SCLC lines. In log phase
growth, all cell lines showed high nuclear hnRNP K
immunostaining (Fig. 1r). This pattern shifted in
cells analyzed from confluent cultures, where the
expression was also found in the cytoplasm and
higher than in log phase growing cells (Fig. 7). In all
clinical specimens studied, normal lung alveoli and
bronchioli were negative (Table 1, Fig. 1o, and p).
In bronchiolar hyperplasia there was a moderate
increase in hnRNP K expression that was almost not
detectable in type II pneumocyte hyperplasia.
Remarkable overexpression of hnRNP K was ob-
served in 60% of the tumors studied with a
predominant expression in adenocarcinomas versus
Fig. 4 Expression of hnRNP A2 (A) and hnRNP B1 (B)
mRNAs in lung cancer cell lines by real time RT-PCR. The
y -axis represents the relation between hnRNP A2 or B1
and GAPDH mRNAs in percentage. Note that the scale is
different between the two graphs.
Fig. 5 Expression of hnRNP C1 (A) and hnRNP C2 (B)
mRNAs in lung cancer cell lines by real time RT-PCR. The
y -axis represents the relation between hnRNP C1 or C2
and GAPDH mRNAs in percentage. Note that the scale is
different between the two graphs.
Fig. 6 Expression of hnRNP K mRNA in lung cancer cell
lines by real time RT-PCR. The y -axis represents the
relation between hnRNP K and GAPDH mRNA in percen-
tage.
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squamous cell carcinomas (79 and 33%, respec-
tively, P/0.006). In these cases the localization of
the protein was mostly nuclear, but half of the
positive cases showed also cytoplasmic immunos-
taining (Fig. 1q). In the two cases of SCLC studied
only nuclear localization of the protein was found.
4. Discussion
In this work we have characterized the expres-
sion and distribution in lung cancer of several
hnRNP proteins involved in mRNA metabolism and
with potential implications in carcinogenesis. We
conclude that the expression of these proteins is
modified in lung cancer as compared with normal
lung epithelium and, therefore, suggest that the
machinery for mRNA metabolism is altered in lung
carcinogenesis. Besides, this abnormal expression
is not a mere consequence of activated prolifera-
tion and can be already observed in preneoplastic
lesions. This interesting fact suggests a potential
use of these molecules, and possibly other mRNA
processing proteins, in early detection of lung
cancer.
To date there is not a single fully validated
biomarker for early detection of lung cancer.
During the past years a lung cancer-associated
monoclonal antibody that recognizes hnRNP A2/B1
[40] has been proposed as a marker for this
purpose. In an attempt to improve our knowledge
on the implication of hnRNP A2/B1 and other
important hnRNP proteins in lung carcinogenesis,
we have characterized the combined expression
pattern and location of hnRNP A1, A2/B1, C1/C2
and K in cancer cell lines as well as normal lung and
early stages of lung cancer. Taken together, our
results show marked differences in the expression
of the hnRNP proteins between normal lung
epithelium and lung tumors. In all cases, an overall
higher expression of the hnRNP proteins was
observed in tumors when compared with normal
lung bronchiolar and alveolar epithelial cells.
Higher hnRNP mRNA levels were found in SCLC
cell lines as compared with most NSCLC cell lines.
As an indication of the activation of the mRNA
processing machinery in each cell line, we have
Fig. 7 Nuclear expression of hnRNP K in H460 cells increases from non-confluent to confluent cultures. In confluent
cells hnRNP K protein is also found in the cytoplasm. Data shown are a representative result of three independent
experiments. (A) Immunocytochemical analysis. Magnification: /500 (inset /1250); scale bar/50 mm. (B) Western
blot analysis. b-Actin expression was used to assess equal loading.
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obtained a comparative value denoted ahnRNP,
consisting in the addition of the mRNA value from
each hnRNP protein analyzed. The fact that SCLC
cell lines consistently have higher ahnRNP suggests
that these types of tumors are more actively
involved in mRNA processing than NSCLC probably
due in part to a higher proliferative capacity of
SCLC cells when compared with NSCLC cells. The
results obtained with the normal bronchial epithe-
lial cells NHBE seem to confirm the already
suggested relationship between proliferation and
increase in the expression of members of the
hnRNP family [38/40]. These proliferating cells
show moderately high levels of hnRNP mRNAs. In
parallel, we have also observed in the biopsies an
increase of the hnRNP protein immunolocalization
in hyperplastic epithelial areas. However, our
results also indicate that the increase in the
expression of hnRNP proteins due to proliferation
does not explain by itself the altered pattern of
expression of hnRNP proteins in lung cancer cell
lines and tissues. This can be exemplified by the
fact that in each cell line there is no correlation
between the levels of all hnRNP proteins. Some cell
lines present high levels of a particular hnRNP
protein but relatively low levels (compared with
other cell lines) of other hnRNP proteins. For
example, H82 cell line shows high levels of hnRNP
A2, relatively low levels of hnRNP C1, and moder-
ate levels of hnRNP C2 and hnRNP K. If only cell
proliferation had accounted for hnRNP protein
overexpression we would have expected a correla-
tive increase in the levels of all hnRNP proteins
from low to high proliferative index, which is not
the case. Moreover, within NSCLC cases, we have
found a significant correlation between the ex-
pression of some hnRNP proteins and the differ-
entiation grade that would rather suggest an
inverse correlation of these hnRNP proteins and
proliferation. In summary, our results show that,
although part of the increase on hnRNP expression
may be due to the high metabolic rate character-
istic of the cycling cells, this activation does not
explain by itself all the alterations in the expres-
sion of these mRNA processing molecules in lung
cancer. All of that is in agreement with previous
works in which hnRNP A1, hnRNP A2/B1 and hnRNP
C1/C2 were less abundant in normal tissues com-
pared with transformed cell lines but only a partial
relation between rate of cell proliferation and
expression of hnRNP proteins was found [39].
The relative expression level of the hnRNP
proteins involved in the 40S-ribonucleoprotein
particle varies from cell line to cell line. This
finding suggests that in different types of tumors
there are alterations from the ‘‘canonical’’ propor-
tion of these proteins: heterotetramers (C1)3C2
and (A2)3B1. This stoichiometry seems important
for the function of the 40S complex and a mod-
ification in the relative levels of each hnRNP
protein, such as what we observe in malignant
lung cells, may alter the processing of the different
pre-mRNAs controlled by these complexes [41].
Interestingly, the pattern of expression of the five
hnRNP proteins is also different when both SCLC
and NSCLC cell lines are compared. These varia-
tions in the pattern of hnRNP expression may be
relevant to the processing of specific mRNAs in
each cell line. More importantly, the stoichiometry
for the hnRNP proteins coming from the same gene
(A2/B1, C1/C2) varies from cell line to cell line,
indicating that there may also exist a regulation in
the splicing of the hnRNP gene itself that could be
thus relevant to its role in the mRNA processing of
other genes. This complex scenario may also apply
to hnRNP A1, for which it has been shown that
mRNA splicing can be regulated by its own protein
[42]. Therefore, to understand the role of hnRNP
proteins in cancer, we need to determine, not only
the expression of every gene but also the relative
proportion of its diverse alternative splicing forms.
Our results support previous reports showing a
high cytoplasmic expression of hnRNP A2/B1 in
primary NSCLC as well as in hyperplastic lesions
[32,43]. Our data also extend the potential rele-
vance of hnRNP A2/B1 to SCLC early detection, as
the mRNA levels of this protein seem to be
particularly high in SCLC. A further finding is that
hnRNP A2/B1 expression is related to the histolo-
gical type of the tumor and the grade of differ-
entiation. Besides, its expression in the tumors is
not homogeneous, with areas of both positive and
negative expression. The biological reason for that
is unknown although it would be of interest to
determine the correlation between the expression
of hnRNP A2/B1 and other sources of tumor
heterogeneity such as the degree of neoangiogen-
esis and the areas of tumor hypoxia. Recent data
indicate that hnRNP A2/B1 expression is down-
regulated in lung cancer cells under hypoxia [44].
Our data also suggest that hnRNP A2/B1 is not the
only RNA binding protein associated with lung
carcinogenesis. Several of the components of the
RNA processing machinery seem to be overex-
pressed in lung cancer and this alteration may be
involved in the process of lung carcinogenesis. In
this sense, we have demonstrated a progressive
increase in nuclear hnRNP A1 expression from
normal lung epithelium, to hyperplastic lesions
(both bronchiolar and alveolar), and to tumors. A
similar trend was found for nuclear immunoreac-
tive hnRNP C1/C2 and hnRNP K.
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hnRNP K is the only hnRNP protein analyzed in
the present study that is not part of the 40S-
ribonucleoprotein complex. We have shown a
noticeable nuclear overexpression of hnRNP K in
tumors when compared with normal lung, with
moderate intensity levels in some hyperplastic
lesions. In the nucleus, hnRNP K binds to the
promoter region of the human c-myc gene and
functions as a transcription factor [19]. Our results
show that the four SCLC cell lines with highest
hnRNP K mRNA levels are those for which amplifi-
cation of at least one of the myc genes has been
reported, whereas no amplification of any myc
gene has been found in three of the four SCLC cell
lines that have lower hnRNP K expression. Further
studies may clarify whether regulation of the
expression of hnRNP K gene is controlled by the
degree of amplification of myc gene. A further
finding is that hnRNP K expression is related to the
histological type, being more expressed in adeno-
carcinomas than in squamous cell carcinomas. In a
subgroup of cases, hnRNP K immunoreactivity was
found not only in the nucleus but also in the
cytoplasm of the tumor cells. The cytoplasmic or
nuclear accumulation of hnRNP K is highly relevant
to determine the role of hnRNP K in a particular
cell, since both nuclear and cytoplasmic functions
have been assigned to this hnRNP protein. Inter-
estingly, in some lung cancer cell lines we observed
a shift from nuclear to nuclear and cytoplasmic
localization of hnRNP K when cells were allowed to
grow to confluence, suggesting a tight regulation of
the localization of the protein in relation to the
cell biological status such as cell cycle or micro-
environment conditions. These findings are in
keeping with the recently reported phosphoryla-
tion-dependent cytoplasmic accumulation of
hnRNP K in HeLa cells after serum stimulation or
constitutive activation of ERK kinase [18].
The observed modifications in the expression of
members of the hnRNP family in lung cancer is in
agreement with the reported abnormalities in
alternative splicing of cancer-related proteins
such as BRCA1 [2], cyclin D1 [3], mdm2 [4], FHIT
[5], TSG101 [6] or VEGF [7]. One of the best
characterized example of a protein with distinct
splicing forms in cancer is CD44. CD44 is a surface
cell-adhesion molecule expressed by several cell
types that can be alternatively spliced to generate
many isoforms, some of which are mainly re-
stricted to tumor cells. Alterations in the expres-
sion of members of the serine-arginine-rich (SR)
family of splicing factors accompany the progres-
sive changes in CD44 alternative splicing in mam-
mary tumorigenesis [45]. hnRNP A1 interacts with
regulatory splice elements in CD44 and has been
proposed as a decisive part of an oncogene-
regulated splice-silencing complex [46,47]. In co-
lon adenocarcinoma, the pattern of CD44 spliced
isoforms seems to be determined by the ratio
between hnRNP A1 and the SR proteins, with hnRNP
A1 antagonizing the SR proteins in the selection of
5? splicing sites [48]. On the other hand, and in
agreement with previous results in myeloid pro-
genitor cells [22], we have observed a relationship
between the expression of hnRNP A1 and Bcl-xL in
SCLC cell lines. In BCR/ABL transformed myeloid
cells, interference with the hnRNP A1 nucleocyto-
plasmic trafficking activity results in an enhanced
susceptibility to apoptosis a reduced level of Bcl-xL
protein [22]. Bcl-x is a member of the Bcl-2 family
with two alternatively spliced forms, Bcl-xL, cap-
able to protect cell from apoptosis, and Bcl-xS, a
pro-apoptotic variant [49]. Thus, the noticeable
increase in the nuclear hnRNP A1 accumulation
from normal to hyperplastic, and to malignant lung
epithelial tissue observed in our study could have
consequences in the splice-choice or the regulation
of expression of several mRNAs, such as those for
CD44 and Bcl-x proteins.
Although we have focused our study on lung
cancer, the RNA processing regulatory proteins may
be also relevant in other types of cancer. Pre-
liminary studies indicate that hnRNP A2/B1 is
abundantly expressed by breast and pancreatic
cancer cell lines and tumors. In both cases, hnRNP
A2/B1 has been proposed as a marker for early
stages of cancer development [23,24]. hnRNP B1 is
also detected in precancerous lesions as well as
advanced lesions of human oral squamous cell
carcinoma, indicating that hnRNP B1 may be a
useful marker for early detection [50]. Surprisingly,
a reduction in cytoplasmic staining for hnRNP A2/
B1 was observed in thyroid carcinomas when
compared with hyperplastic and adenomatous le-
sions [51]. Altered expression of other alternative
splicing regulatory factors has been reported in in
vitro models of cellular transformation [52]. hnRNP
A1 has been implicated in the genesis of variant
pre-mRNA splicing patterns observed between two
types of brain tumors, oligodendrogliomas and
astrocytomas [21], and a variety of RNA binding
proteins have been related to other epithelial [45]
and non-epithelial tumors [22,53/55]. Finally, a
development of sarcomas has been observed in
transgenic mice that overexpress hnRNP D [56], a
member of the hnRNP family that has been shown
to control the stability of several mRNAs, including
that for proto-oncogenes, cytokines, or other
signaling molecules.
In conclusion, we have determined the expres-
sion of several members of the family of the hnRNP
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proteins in normal and malignant lung. Each of
these proteins shows different levels of expression
and distribution in normal and tumor lung. Our data
suggest that critical cellular processes related to
RNA maturation may be deregulated in lung carci-
nogenesis, giving rise to novel tumor-specific
protein patterns. An understanding of the regula-
tory mechanisms of alternative splicing occurring
along with neoplastic transformation may help to
elucidate some of the causes of abnormal gene
expression in lung cancer. More comprehensive
studies of the role of the hnRNP proteins in lung
carcinogenesis may allow the development of high
throughput platforms in which the detailed analysis
of the expression of every molecule related to
mRNA processing, including hnRNP proteins, may
allow the determination of a specific ‘‘mRNA
processing machinery profile’’ of a particular
tumor. The clinical significance of this profiling in
terms of early detection, prognosis and patient-
based treatment should also be explored in the
future.
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